Orphan drugs - Authors' reply

Affiliations

¹ Muhimbili University of Health and Allied Sciences, Dar-es-Salaal, Tanzania.
² Department of Pharmacy, Azienda Ospedaliera Universitaria Integrata Verona, Italy.
³ Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Rare Disease Unit, Bergamo, Italy.
⁴ Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 24126 Bergamo, Italy; Department of Clinical and Biomedical Sciences, University of Milan, Italy. Electronic address: giuseppe.remuzzi@marionegri.it.

Comment

Lucio Luzzatto et al. Lancet. 2019.

. 2019 Apr 20;393(10181):1595-1596.

doi: 10.1016/S0140-6736(19)30014-5.

¹ Muhimbili University of Health and Allied Sciences, Dar-es-Salaal, Tanzania.
² Department of Pharmacy, Azienda Ospedaliera Universitaria Integrata Verona, Italy.
³ Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Rare Disease Unit, Bergamo, Italy.
⁴ Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 24126 Bergamo, Italy; Department of Clinical and Biomedical Sciences, University of Milan, Italy. Electronic address: giuseppe.remuzzi@marionegri.it.

No abstract available

Comment on

Orphan drugs.
Cainelli F, Vento S. Cainelli F, et al. Lancet. 2019 Apr 20;393(10181):1594. doi: 10.1016/S0140-6736(19)30016-9. Lancet. 2019. PMID: 31007197 No abstract available.
Orphan drugs.
Messori A, Attanasio F, Trippoli S, Banfi R. Messori A, et al. Lancet. 2019 Apr 20;393(10181):1595. doi: 10.1016/S0140-6736(19)30015-7. Lancet. 2019. PMID: 31007198 No abstract available.
Orphan drugs.
Puig-Junoy J, Campillo-Artero C. Puig-Junoy J, et al. Lancet. 2019 Apr 20;393(10181):1595. doi: 10.1016/S0140-6736(19)30017-0. Lancet. 2019. PMID: 31007200 No abstract available.